United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

Ahmad A. Tarhini,Sandra J. Lee,F. Stephen Hodi,Uma N. M. Rao,Gary I. Cohen,Omid Hamid,Laura F. Hutchins,Jeffrey A. Sosman,Harriet M. Kluger,Vernon K. Sondak,Henry B. Koon,Donald P. Lawrence,Kari Kendra,David R. Minor,Carrie B. Lee,Mark R. Albertini,Lawrence E. Flaherty,Teresa M. Petrella,John M. Kirkwood

United States Intergroup E1609: A phase III randomized study of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon-α2b for resected high-risk melanoma.

2019

Ahmad A. Tarhini
Sandra J. Lee
F. Stephen Hodi
Uma N. M. Rao
Gary I. Cohen
Omid Hamid
Laura F. Hutchins
Jeffrey A. Sosman
Harriet M. Kluger
Vernon K. Sondak
Henry B. Koon
Donald P. Lawrence
Kari Kendra
David R. Minor
Carrie B. Lee
Mark R. Albertini
Lawrence E. Flaherty
Teresa M. Petrella
John M. Kirkwood

9504Background: Phase III adjuvant trials reported significant benefits in relapse-free survival (RFS) for 6 FDA-approved regimens and overall survival (OS) for HDI and ipi10 versus observation or ...

Keywords:

Melanoma
Adjuvant
Oncology
Ipilimumab
Randomized controlled trial
Pathology
Interferon
Internal medicine
Medicine
Adjuvant Trials
overall survival
interferon α2b

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations